NICE backs retifanlimab for advanced anal canal cancer
NICE has recommended retifanlimab for adults with anal canal cancer that has spread and cannot be removed through surgery, opening NHS access to the first drug the agency has endorsed for this specific disease. The decision pairs the PD-1 inhibitor with platinum-based chemotherapy, specifically carboplatin plus paclitaxel, for untreated metastatic disease or inoperable locally recurrent squamous cell anal canal cancer.
The timing matters for a cancer that has long had few systemic options and poor outcomes once it spreads. For eligible patients in England, the treatment is available immediately on the NHS.
The disease burden is small in absolute numbers but clinically severe. An estimated 1,600 new anal cancer diagnoses occurred each year in the UK from 2017 to 2019, and about two-thirds were in women. Human papillomavirus infection is linked to roughly 90% of UK cases, with HIV also a recognized risk factor. Symptoms often include rectal bleeding, pain, severe itching around the anal area, and bowel habit changes, yet patient experts told NICE’s committee that low awareness still delays diagnosis until the cancer is advanced.
Survival gains seen when immunotherapy is added to chemotherapy
Retifanlimab is a monthly intravenous infusion. Mechanistically, it targets programmed death receptor-1, or PD-1, on T-cells. By blocking this checkpoint, the drug helps release immune restraint and makes it easier for the body to recognize and attack tumor cells. In anal canal cancer, where virus-driven oncogenic pathways may contribute to immune escape, that approach has a clear biological rationale alongside cytotoxic chemotherapy.
Clinical trial evidence supported the recommendation with two linked signals: longer time before the disease progressed and longer overall survival. Patients receiving retifanlimab with carboplatin and paclitaxel had a median progression-free survival of 9.3 months, compared with 7.4 months for those given placebo with chemotherapy. The overall survival difference was larger: 32.8 months versus 22.2 months. Some patients had much longer-lasting responses, suggesting a subset derived durable benefit rather than a brief delay in progression.
A 1.9-month median gain in progression-free survival may sound modest in isolation. In metastatic anal cancer, where therapeutic options have been sparse, the combination also translated into a survival advantage that exceeded nine months.
Why this approval matters for a rare and overlooked disease
Advanced anal cancer has remained difficult to treat because many patients are diagnosed late and because standard chemotherapy has carried most of the treatment burden for years. For people whose cancer has already spread, five-year survival is around 20%, compared with around 90% when the disease has not spread. Those numbers reflect the point at which a tumor becomes both biologically more aggressive and harder to eliminate with local therapies alone.
Retifanlimab does not replace chemotherapy in this setting; it deepens it. The added immune checkpoint blockade may extend the period during which residual disease stays under control, while also offering the possibility of more durable immune-mediated responses in some patients. That distinction is important at the bedside, where the goal is not only to shrink tumors but also to keep them suppressed long enough for patients to live longer and spend more time without overt progression.
Helen Knight, director of medicines evaluation at NICE, described anal cancer as a devastating disease with limited treatments and said the recommendation offers renewed hope to hundreds of people. NHS England’s national clinical director for cancer, Professor Peter Johnson, called the approval one of the most significant steps in decades for people with advanced anal cancer and said fast-tracking means eligible patients can begin treatment right away.
Cost-effectiveness, access, and the committee’s decision
NICE’s independent appraisal committee applied a severity modifier of 1.2 to this medicine, allowing a higher cost-effectiveness threshold because the condition is classed as high or medium severity. The company also has a commercial arrangement through a simple patient access scheme that provides a confidential discount to the NHS.
Those economic details matter because they determine whether a biologically credible therapy becomes a real option in routine care. In rare cancers, access is often as decisive as efficacy. A treatment can show meaningful clinical benefit, yet still fail to reach patients unless pricing and appraisal align with the NHS framework.
NICE also said it is now publishing guidance 30% faster for medicines and 9% faster for healthtech than before April 2024, after changes from its transformation programme. In this case, faster appraisal compressed the gap between regulatory authorization and routine access.
A new option for patients who have had too few
Bowel Cancer UK and the Anal Cancer Foundation both welcomed the recommendation, pointing to the need for more treatment options and greater recognition of a cancer that has often been overlooked. Their comments reflect a long-standing clinical problem: anal cancer is uncommon, but the burden on patients and families is substantial because diagnosis is frequently delayed and advanced disease leaves little room for error.
The approval does not solve that upstream problem. Awareness of symptoms, earlier referral, and prompt diagnosis still determine who reaches the stage where systemic therapy can help most. The new regimen changes the treatment ceiling for people already facing metastatic or inoperable recurrent disease, but the next unanswered question is how earlier detection might shift outcomes before spread occurs. For now, retifanlimab gives clinicians a new first-line option where nearly every extra month of disease control counts.